Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ:DARE) initiated a Phase 2 randomized, double-blind, placebo-controlled study of DARE-HPV, a vaginal insert containing lopinavir/ritonavir for persistent high-risk HPV infection, which currently has no FDA-approved pharmacologic treatments. The ARPA-H–funded $10 million program expects topline data in 2027.
Daré Bioscience (NASDAQ:DARE) reported Q1 2026 results and outlined upcoming commercial and clinical milestones. First direct product revenue is expected in June 2026 from U.S. launch of Flora Sync LF5, a vaginal probiotic distributed via the DARE Health Hub.
Key programs include DARE to PLAY sildenafil cream (dispensing targeted summer 2026), DARE to RECLAIM hormone therapy (revenue targeted 2027), a Phase 3 trial of Ovaprene with a second positive DSMB review, and DARE-HPV, advancing to Phase 2 with a $10 million ARPA-H contract.
Daré Bioscience (NASDAQ: DARE) reported positive interim Phase 3 results for Ovaprene, a novel hormone-free, monthly intravaginal contraceptive. A second independent DSMB review of safety data recommended the trial continue without modification.
Interim data from 339 women (1,789 cycles) showed an approximately 9% pregnancy rate, consistent with expectations, no serious device-related adverse events, and no increase or new types of adverse events with prolonged use. About 12% discontinued due to vaginal odor, a 5% decrease versus July 2025 data, and a majority of completers were likely to use Ovaprene if available. The single-arm, open-label Phase 3 study targets at least 2,500 exposure cycles in 2026, with the Pearl Index over 13 cycles as the primary endpoint.
Dare Bioscience (NASDAQ: DARE) will host its First Quarter 2026 financial results conference call and live webcast on May 14, 2026 at 4:30 p.m. ET to review results for the quarter ended March 31, 2026 and provide a company update. The webcast will be archived through May 28, 2026.
Dial-in numbers, conference ID 2531472, and webcast access are available in the Investors section of the company's website.
Daré Bioscience (NASDAQ: DARE) reported full-year 2025 results and a business update on March 26, 2026. Key facts: $24.7M cash, $3.4M working capital, $20.8M net equity proceeds, and significant non-dilutive funding including $13.6M from Gates and $4.5M ARPA-H.
Commercial launches planned: DARE to PLAY dispensing and Flora Sync LF5 consumer sales expected Q2 2026; DARE to RECLAIM targeted in 2027. Ovaprene Phase 3 enrollment expected to complete in 2026; DARE-HPV advancing to Phase 2 with ARPA-H support.
Daré Bioscience (NASDAQ: DARE) announced DARE to PLAY™ Sildenafil Cream, a prescription topical sildenafil product developed and clinically studied specifically for women, and available as a Section 503B compounded product. Clinical studies showed increased genital blood flow within 10–15 minutes and improved arousal sensations using clinically validated endpoints. Daré highlights the product as non‑hormonal, fast‑acting, and ready for prescribers. The company is concurrently conducting a Regulation A offering open to all investors to support its women’s health pipeline.
Daré Bioscience (NASDAQ: DARE) will host a conference call and live webcast at 4:30 p.m. ET on March 26, 2026 to review full year 2025 financial results and provide a company update.
Dial-in numbers are (646) 307-1963 or (800) 715-9871 with conference ID 1717423. The webcast is at http://ir.darebioscience.com and will be archived for replay until April 9, 2026.
Daré Bioscience (NASDAQ: DARE) received a revised NIH Notice of Award, obligating approximately $2.0 million total for DARE-PTB1, an investigational intravaginal ring (IVR) to prevent preterm birth. The notice, dated March 11, 2026, extends the second tranche (about $1.0 million) through November 30, 2026.
DARE-PTB1 is designed to deliver bio-identical progesterone continuously for up to a 14-day period and leverages learnings from prior DARE IVR hormone trials. The award reflects Daré's use of non-dilutive funding to advance its women's health pipeline.
Daré Bioscience (NASDAQ: DARE) announced CEO Sabrina Martucci Johnson’s participation in a Virtual Investor segment highlighting the FDA clearance of the IND for DARE-HPV on March 12, 2026 and plans to advance the program into a Phase 2 clinical study.
The CEO outlined how DARE-HPV would differ from current management of persistent high-risk HPV, noted the absence of any FDA-approved drug therapy for that condition, described anticipated timelines, potential risks, upcoming catalysts, and cited non-dilutive ARPA-H funding supporting the program.
Daré Bioscience (NASDAQ: DARE) announced FDA clearance of its IND for DARE-HPV, enabling initiation of a planned Phase 2 study for a topical lopinavir/ritonavir vaginal insert to treat persistent high‑risk HPV infection. The program is supported by a $10 million ARPA-H contract, with $6.5 million received to date. The study aims to evaluate safety and antiviral activity and the company is preparing to start the trial in 2026.
DARE-HPV targets an unmet need: there are currently no FDA‑approved pharmacologic treatments for high‑risk HPV, the primary cause of cervical cancer.